Hypophosphatasia Clinical Trials

53 clinical trials for Hypophosphatasia across international registries, including 12 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Prospective, Longitudinal, Observational Registry of Adult Patients With Hypophosphatasia (REG-HYPO) — RECRUITING
• A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1 — RECRUITING · PHASE1
• The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia — RECRUITING
• A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN1850 Versus Placebo Administered Subcutaneously in Pediatric (2 to < 12 years of age) Participants with Hypophosphatasia Who Have Not Received Previous Treatment with Asfotase Alfa — RECRUITING · PHASE3
• Natural History Study of Patients With Hypophosphatasia (HPP) — RECRUITING
• Registry of Patients With Hypophosphatasia — RECRUITING
• A Prospective Sub-Study of the Global Hypophosphatasia Registry — RECRUITING
• Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford — RECRUITING
• Characteristics of Hypophosphatasia in Adult Patients in Rheumatology and Their Value in Developing an Algorithm to HPP-diagnosis - the COHIR Multi-center Study — RECRUITING
• A PHASE 3, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM, ACTIVE-CONTROLLED, MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF ALXN1850 VERSUS ASFOTASE ALFA ADMINISTERED SUBCUTANEOUSLY IN PEDIATRIC PARTICIPANTS (2 TO < 12 YEARS OF AGE) WITH HYPOPHOSPHATASIA (HPP) PREVIOUSLY TREATED WITH ASFOTASE ALFA — RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF ALXN1850 VERSUS PLACEBO ADMINISTERED SUBCUTANEOUSLY IN PEDIATRIC (2 TO < 12 YEARS OF AGE) PARTICIPANTS WITH HYPOPHOSPHATASIA WHO HAVE NOT RECEIVED PREVIOUS TREATMENT WITH ASFOTASE ALFA — RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF ALXN1850 (RECOMBINANT ALKALINE PHOSPHATASE) ADMINISTERED SUBCUTANEOUSLY IN ADOLESCENT (12 TO < 18 YEARS OF AGE) AND ADULT PARTICIPANTS WITH HYPOPHOSPHATASIA WHO HAVE NOT PREVIOUSLY BEEN TREATED WITH ASFOTASE ALFA — RECRUITING · PHASE3
• Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP) — OTHER · PHASE2
• Access Program for Asfotase Alfa — COMPLETED · PHASE4
• A Randomised, Placebo-Controlled, Double-Blind, Single-Ascending Dose and Multiple-Ascending Dose First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered ALE1 With or Without Food in Healthy Adult Participants and Adult Patients With Hypophosphatasia — NOT_YET_RECRUITING · PHASE2
• Early Check: Expanded Screening in Newborns — ACTIVE_NOT_RECRUITING
• Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa — ACTIVE_NOT_RECRUITING · PHASE3
• Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP — ACTIVE_NOT_RECRUITING · PHASE3
• United States Hypophosphatasia Molecular Research Center — COMPLETED
• Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa — ACTIVE_NOT_RECRUITING · PHASE3
• Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia — WITHDRAWN · PHASE4
• A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN1850 (Recombinant Alkaline Phosphatase) Administered Subcutaneously in Adolescent (12 to < 18 years of age) and Adult Participants with Hypophosphatasia Who Have Not Previously Been Treated with Asfotase Alfa (Hickory) — TERMINATED · PHASE3
• Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia — COMPLETED · PHASE1
• Study of ALXN1850 in Participants With Hypophosphatasia (HPP) — COMPLETED · PHASE1
• An Interventional, Prospective Open-Label Study of Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE) — OTHER · PHASE4
• Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa) — COMPLETED
• A Phase 3, Randomized, Open-label, Parallel-arm, Active-controlled, Multicenter Study to Evaluate Safety and Efficacy of ALXN1850 Versus Asfotase Alfa Administered Subcutaneously in Pediatric Participants (2 to < 12 years of age) with Hypophosphatasia (HPP) Previously Treated with Asfotase Alfa (Chestnut) — OTHER · PHASE3
• Characteristics of Hypophosphatasia in Adult Patients in Rheumatology — OTHER
• Characterisation of Adult-Onset Hypophosphatasia — COMPLETED
• Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP) — WITHDRAWN · PHASE2
• Circulating miRNAs and Bone Microstructure in Adults With Hypophosphatasia — OTHER
• The PORTRAIT Study — OTHER
• Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP) — COMPLETED · PHASE2
• Evaluate and Monitor Physical Performance of Adults Treated With Asfotase Alfa for Hypophosphatasia — COMPLETED
• Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) — COMPLETED
• Evaluation of Bone Architecture and Bone Strength in Adults With Hypophosphatasia (HPP) — OTHER
• Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic Disease — WITHDRAWN · PHASE4
• Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP) — COMPLETED · PHASE2
• A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP) — COMPLETED
• Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP) — COMPLETED · PHASE1
• Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP) — COMPLETED · PHASE2
• Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP) — COMPLETED
• Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP) — COMPLETED · PHASE1
• Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP) — OTHER
• Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP) — COMPLETED · PHASE2
• Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP) — COMPLETED · PHASE2
• Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09 — COMPLETED
• Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP) — COMPLETED · PHASE2
• Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP) — COMPLETED · PHASE2
• Health Burden of Hypophosphatasia — COMPLETED

Refine this search